Author:
Shang Linyue,Wei Huimei,Deng Jing,Stewart Madeline J.,LeSaint Johnathan E.,Kyomuhangi Annet,Park Shawn,Maul Elise C.,Zhan Chang-Guo,Zheng Fang
Abstract
AbstractIt is recognized as a promising therapeutic strategy for cocaine use disorder to develop an efficient enzyme which can rapidly convert cocaine to physiologically inactive metabolites. We have designed and discovered a series of highly efficient cocaine hydrolases, including CocH5-Fc(M6) which is the currently known as the most efficient cocaine hydrolase with both the highest catalytic activity against (−)-cocaine and the longest biological half-life in rats. In the present study, we characterized the time courses of protein appearance, pH, structural integrity, and catalytic activity against cocaine in vitro and in vivo of a CocH5-Fc(M6) bulk drug substance produced in a bioreactor for its in vitro and in vivo stability after long-time storage under various temperatures (− 80, − 20, 4, 25, or 37 °C). Specifically, all the tested properties of the CocH5-Fc(M6) protein did not significantly change after the protein was stored at any of four temperatures including − 80, − 20, 4, and 25 °C for ~ 18 months. In comparison, at 37 °C, the protein was less stable, with a half-life of ~ 82 days for cocaine hydrolysis activity. Additionally, the in vivo studies further confirmed the linear elimination PK profile of CocH5-Fc(M6) with an elimination half-life of ~ 9 days. All the in vitro and in vivo data on the efficacy and stability of CocH5-Fc(M6) have consistently demonstrated that CocH5-Fc(M6) has the desired in vitro and in vivo stability as a promising therapeutic candidate for treatment of cocaine use disorder.
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. FDA News Release on October 04, 2023: FDA Takes Steps to Advance the Development of Novel Therapies for Stimulant Use Disorders (https://www.fda.gov/news-events/press-announcements/fda-takes-steps-advance-development-novel-therapies-stimulant-use-disorders?utm_medium=email&utm_source=govdelivery) (2023).
2. Schwartz, E. K. C., Wolkowicz, N. R., De Aquino, J. P., MacLean, R. R. & Sofuoglu, M. Cocaine use disorder (CUD): Current clinical perspectives. Subst. Abuse Rehabil. 13, 25–46 (2022).
3. Moreno, A. Y. & Janda, K. D. Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence. Pharmacol. Biochem. Behav. 92(2), 199–205 (2009).
4. Wei, H., Shang, L., Zhan, C.-G. & Zheng, F. Effects of cebranopadol on cocaine-induced hyperactivity and cocaine pharmacokinetics in rats. Sci. Rep. 10, 9254. https://doi.org/10.1038/s41598-020-66250-z (2020).
5. Wei, H., Zhang, T., Zhan, C.-G. & Zheng, F. Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety considerations. Neuropharmacology 172, 108128 (2020).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献